Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28341825 | 0.85 | FGFR4 (0.36) | CSNK1A1CLK4CYP11B2TRPV4PGK1 | |
| SCHEMBL25841900 | 0.83 | PGK1 (0.39) | CSNK1A1CLK4CYP11B2TRPV4PGK1 | |
| SCHEMBL28341854 | 0.83 | NNMT (0.49) | CSNK1A1CLK4AR | |
| SCHEMBL28344564 | 0.83 | CYP11B2 (0.32) | CSNK1A1CLK4CYP11B2PGK1 | |
| SCHEMBL21927208 | 0.80 | UHRF1 (0.38) | CSNK1A1CLK4CYP11B2ALDH1A1NPSR1 | |
| SCHEMBL1286023 | 0.78 | CSNK1A1 (0.44) | CSNK1A1CLK4CYP11B2TRPV4PGK1 | |
| SCHEMBL317517 | 0.78 | UHRF1 (0.46) | CSNK1A1CLK4CYP11B2ALDH1A1NPSR1 | |
| SCHEMBL29505699 | 0.78 | UHRF1 (0.46) | CSNK1A1CLK4CYP11B2ALDH1A1NPSR1 | |
| SCHEMBL30445578 | 0.78 | CSNK1A1 (0.44) | CSNK1A1CLK4CYP11B2TRPV4PGK1 | |
| SCHEMBL30203623 | 0.75 | CSNK1A1 (0.50) | CSNK1A1CLK4CYP11B2TRPV4PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| EP-3089966-B1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | ESTRYX PHARMA LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| EP-3648753-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2020-05-13 | — | — | EP | disclosed |
| CN-111093645-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
| WO-2019010295-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2019-01-10 | — | — | WO | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1414802-B1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1572655-A2 | NOVEL ARYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| CN-1630637-A | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | CN | disclosed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| EP-1414802-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011830-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002090332-A2 | NOVEL AEYLHETEROALKYLAMINΕ DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | CSNK1A1 338/4885CLK4 2989/4885CYP11B2 391/4885 |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | CSNK1A1 1459/4885CLK4 3878/4885CYP11B2 4044/4885 |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | GPR119, INSR, LYAR | CSNK1A1 1459/4885CLK4 3878/4885CYP11B2 4044/4885 |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | CSNK1A1 1459/4885CLK4 3878/4885CYP11B2 4044/4885 |
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS1, NOS2 | CSNK1A1 300/4885CLK4 2007/4885CYP11B2 143/4885 |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | CSNK1A1 32/4885CLK4 1724/4885CYP11B2 2333/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | CSNK1A1 1459/4885CLK4 3878/4885CYP11B2 4044/4885 |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | CSNK1A1 1459/4885CLK4 3878/4885CYP11B2 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.